Transcatheter aortic valve implantation (TAVI) is a novel therapeutic option for patients with severe symptomatic aortic stenosis (AS) at excessive or high surgical risk for conventional surgical aortic valve replacement. First commercialised in Europe in 2007, TAVI growth has been exponential among some Western European nations, though recent evidence suggests heterogeneous adoption of this new and expensive therapy. Herein, we review the evidence describing the utilisation of TAVI in Western Europe.

Interventional Cardiology (London)
Erasmus MC: University Medical Center Rotterdam

Mylotte, D., Osnabrugge, R., Martucci, G., Lange, R., Kappetein, A. P., & Piazza, N. (2014). Adoption of transcatheter aortic valve implantation in western Europe. Interventional Cardiology (London), 9(1), 37–40. Retrieved from